ODM-109 ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	26

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

diseases per page:

Showing 1 to 10 of 26 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004180-31-FR (EUCTR)	31/01/2020	07/11/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...
2	EUCTR2018-004180-31-IE (EUCTR)	16/12/2019	02/08/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...
3	EUCTR2018-004180-31-NL (EUCTR)	02/10/2019	23/07/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;France;Canada;Belgium;Australia;Net ...
4	EUCTR2018-004180-31-GB (EUCTR)	05/09/2019	01/11/2019	An open label extension for patients completing study 3119002 to studythe effects of oral Levosimend ...	Effects of oral levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;France;Canada;Belgium;Australia;Net ...
5	EUCTR2018-004180-31-AT (EUCTR)	22/08/2019	03/05/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...
6	EUCTR2018-004180-31-FI (EUCTR)	15/08/2019	25/04/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...
7	EUCTR2018-004180-31-IT (EUCTR)	24/07/2019	18/01/2021	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: [ODM-109] INN or Proposed INN: LEVOSIMENDAN	ORION CORPORATION ORION PHARMA	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;France;Canada;Belgium;Australia;Ger ...
8	NCT03948178 (ClinicalTrials.gov)	June 26, 2019	7/5/2019	Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension	Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Exte ...	Amyotrophic Lateral Sclerosis	Drug: Levosimendan	Orion Corporation, Orion Pharma	NULL	Completed	18 Years	120 Years	All	227	Phase 3	Spain
9	EUCTR2018-004180-31-DE (EUCTR)	17/06/2019	12/04/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...
10	EUCTR2018-004180-31-ES (EUCTR)	16/05/2019	12/04/2019	An open label extension for patients completing study 3119002 to study the effects of oral Levosimen ...	Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label exte ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term ...	Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 INN or Proposed INN: LEVOSIMENDAN	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Australia;Ger ...

First Previous1 2 3Next Last